What's Happening?
GRAIL, Inc. has reported significant growth in the use of its Galleri multi-cancer early detection test, with a 35% increase in test volume and a 24% rise in revenue year-over-year. The Galleri test, which uses a simple blood draw to detect DNA shed by
cancer cells, has shown strong performance in identifying cancers at early stages. Recent studies, including NHS-Galleri and PATHFINDER 2, demonstrated the test's ability to detect a wide range of cancers, many of which lack recommended screening options. The test accurately identified the cancer signal origin over 90% of the time, facilitating efficient diagnostic workups.
Why It's Important?
The Galleri test represents a significant advancement in cancer screening, offering the potential to detect cancers earlier than traditional methods. Early detection is crucial for improving treatment outcomes and survival rates. By identifying cancers before symptoms appear, the test could reduce the burden of late-stage cancer diagnoses and improve patient prognosis. The test's ability to detect multiple cancer types with a single blood draw could revolutionize cancer screening and lead to more widespread adoption of early detection strategies.
What's Next?
GRAIL anticipates an FDA advisory committee review of the Galleri test's Premarket Approval application in the fall. The company is also expanding access to the test through new partnerships, including a collaboration with Priority Health to offer the test to self-insured employer groups. These developments could lead to broader availability and acceptance of the Galleri test, potentially transforming cancer screening practices in the U.S. and beyond.
